1. Home
  2. INDP vs YDKG Comparison

INDP vs YDKG Comparison

Compare INDP & YDKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.03

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo Yueda Digital Holding Class A Ordinary Share

YDKG

Yueda Digital Holding Class A Ordinary Share

N/A

Current Price

$0.94

Market Cap

5.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
YDKG
Founded
2000
2005
Country
United States
China
Employees
N/A
17
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
INDP
YDKG
Price
$2.03
$0.94
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.4K
100.5K
Earning Date
05-13-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.02
52 Week High
$13.24
$3.90

Technical Indicators

Market Signals
Indicator
INDP
YDKG
Relative Strength Index (RSI) 50.43 46.38
Support Level $1.64 $0.81
Resistance Level $1.99 $1.01
Average True Range (ATR) 0.18 0.08
MACD 0.03 0.00
Stochastic Oscillator 53.33 31.30

Price Performance

Historical Comparison
INDP
YDKG

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

Share on Social Networks: